THE EXPRESSION OF THE PI3K/AKT/mTOR PATHWAY AS A PROGNOSTIC FACTOR IN PATIENTS WITH ADVANCED HIGH GRADE SEROUS OVARIAN CARCINOMA TREATED WITH NEOADJUVANT CHEMOTHERAPY

2016 ◽  
Author(s):  
Lubomir Bodnar
Keyword(s):  
Prognostic Factor ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Mtor Pathway ◽  
High Grade ◽  
Serous Ovarian Carcinoma

Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy

2015 ◽  
Vol 137 ◽  
pp. 43
Author(s):  
J.M. Stewart ◽  
A.A. Tone ◽  
M.Q. Bernardini ◽  
S.E. Ferguson ◽  
J. Dodge ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
High Grade ◽  
Serous Ovarian Carcinoma

Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma

2016 ◽  
Vol 141 ◽  
pp. 151-152
Author(s):  
R.C. Arend ◽  
Z.C. Dobbin ◽  
D.K. Crossman ◽  
B.K. Erickson ◽  
J.D. Boone ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Molecular Response ◽  
High Grade ◽  
Serous Ovarian Carcinoma ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma

2017 ◽  
Vol 24 (12) ◽  
pp. 2089-2100 ◽  
Author(s):  
Yuqiong Wang ◽  
Xiyu Zhang ◽  
Wei Tang ◽  
Zhenghong Lin ◽  
Limei Xu ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Mtor Pathway ◽  
High Grade ◽  
Serous Ovarian Carcinoma

scholarly journals ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma

2015 ◽  
Vol 36 (7) ◽  
pp. 739-747 ◽  
Author(s):  
Dong-Joo Cheon ◽  
Andrew J. Li ◽  
Jessica A. Beach ◽  
Ann E. Walts ◽  
Hang Tran ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Ovarian Carcinoma ◽  
Molecular Subtype ◽  
High Grade ◽  
Serous Ovarian Carcinoma
Sign in / Sign up

Export Citation Format

Share Document